Get the Stockscreener App
21.47
0.05%
0.010
After Hours:
21.46
-0.010
-0.05%
Day One Biopharmaceuticals Inc stock is traded at $21.47, with a volume of 1.03M.
It is up +0.05% in the last 24 hours and up +0.75% over the past month.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
See More
Previous Close:
$21.46
Open:
$21.47
24h Volume:
1.03M
Relative Volume:
0.25
Market Cap:
$2.22B
Revenue:
$158.18M
Net Income/Loss:
$-107.32M
P/E Ratio:
-20.60
EPS:
-1.0421
Net Cash Flow:
$-107.58M
1W Performance:
+0.14%
1M Performance:
+0.75%
6M Performance:
+175.96%
1Y Performance:
+198.61%
1-Day Range:
$21.46
$21.48
1-Week Range:
$21.45
$21.49
52-Week Range:
$5.635
$21.49
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
Name
Day One Biopharmaceuticals Inc
Sector
Industry
Phone
650 484-0899
Address
1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE
Compare DAWN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
21.47 | 2.22B | 158.18M | -107.32M | -107.58M | -1.0421 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-13-26 | Resumed | TD Cowen | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Oct-09-24 | Reiterated | Needham | Buy |
| Aug-01-24 | Upgrade | BofA Securities | Underperform → Buy |
| Apr-24-24 | Reiterated | Needham | Buy |
| Apr-25-23 | Downgrade | BofA Securities | Buy → Underperform |
| Feb-08-23 | Initiated | CapitalOne | Overweight |
| Feb-03-23 | Initiated | Oppenheimer | Perform |
| Dec-15-22 | Initiated | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Dec-05-22 | Initiated | Goldman | Buy |
| Dec-01-22 | Initiated | BofA Securities | Buy |
View All
Day One Biopharmaceuticals Inc Stock (DAWN) Latest News
[SC 14D9/A] Day One Biopharmaceuticals, Inc. Amended Tender Offer Recommendation - Stock Titan
[SC TO-T/A] Day One Biopharmaceuticals, Inc. Amended Third-Party Tender Offer | DAWN SEC FilingForm SC TO-T/A - Stock Titan
Access Industries group tenders Day One (DAWN) 12.9M-share stake at $21.50 - Stock Titan
Day One Biopharmaceuticals stock reaches 52-week high of $21.48 By Investing.com - Investing.com Australia
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 1-Year HighHere's What Happened - MarketBeat
Day One Biopharmaceuticals stock reaches 52-week high of $21.48 - Investing.com
Day One Biopharma to be acquired by Servier for $2.5B - MSN
Market Review: Is Day One Biopharmaceuticals Inc forming higher highs and higher lowsTrend Reversal & Trade Opportunity Analysis Reports - baoquankhu1.vn
DAWN Stock Price, Quote & Chart | DAY ONE BIOPHARMACEUTICALS I (NASDAQ:DAWN) - ChartMill
Earnings Recap: How does Day One Biopharmaceuticals Inc compare to its peers2026 Setups & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders? - Finviz
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Terns Therapeutics, Inc. (Nasdaq – TERN), Whitestone REIT (NYSE – WSR), Rallybio Corporation (Nasdaq – RLYB), Day One Biopharmaceuticals, Inc. (Nasda - ChartMill
(DAWN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Biotech M&A Spree Helps Lead SBIO to March Gains - ETF Database
Chart Watch: How does Day One Biopharmaceuticals Inc compare to its peers - baoquankhu1.vn
Servier (DAWN) wins FTC early HSR termination, clearing HSR hurdle for tender offer - Stock Titan
HSR waiting period ends for Day One Biopharma (NASDAQ: DAWN) — Offer stays subject to conditions - Stock Titan
Swing Trade: How is Day One Biopharmaceuticals Inc managing supply chain issues2026 Technicals & Weekly Market Pulse Alerts - baoquankhu1.vn
FMR LLC holds 23,639.69 shares in Day One Biopharmaceuticals (NASDAQ: DAWN) amendment - Stock Titan
JonesTrading Maintains Day One Biopharmaceuticals(DAWN.US) With Hold Rating, Maintains Target Price $21.5 - Moomoo
Aug Levels: Is Day One Biopharmaceuticals Inc a strong growth stock2026 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
Is Day One Biopharmaceuticals Inc a turnaround story2026 Key Highlights & Trade Opportunity Analysis - baoquankhu1.vn
Day One Biopharmaceuticals price target raised to $36 from $32 at JPMorgan - tipranks.com
SG Americas Securities LLC Buys 323,747 Shares of Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Hits New 12-Month HighShould You Buy? - MarketBeat
Baker McKenzie Advises Servier on the Acquisition of Day One Biopharmaceuticals for Approximately USD 2.5 Billion - Legal Desire Media and Insights
DAWN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Hennion & Walsh Asset Management Inc. Buys 218,383 Shares of Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
Breakout Move: Is Day One Biopharmaceuticals Inc a turnaround storyWeekly Stock Summary & Community Verified Trade Signals - baoquankhu1.vn
Earnings Miss: Is Day One Biopharmaceuticals Inc a top pick in the sectorTake Profit & Safe Capital Growth Stock Tips - baoquankhu1.vn
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Down 20.3% in March - MarketBeat
Day One Biopharmaceuticals (DAWN) price target decreased by 10.27% to 21.16 - MSN
(DAWN) Risk Channels and Responsive Allocation - Stock Traders Daily
Are SEM, DAWN, VRE Obtaining Fair Deals for their Shareholders? - The Malaysian Reserve
Day One Biopharmaceuticals Executives Sell Shares Amid Legal Firm's Scrutiny of $21.50 Offer - Bitget
Vanguard amends holdings for Day One Biopharmaceuticals (NASDAQ: DAWN), reports 0 shares - Stock Titan
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc.DAWN - The AI Journal
Servier adds exhibit to Day One Biopharma tender offer (DAWN) - Stock Titan
Servier offers $21.50 per share for Day One (NASDAQ: DAWN) in agreed deal - Stock Titan
Servier (DAWN) offers $21.50 in cash to buy Day One Biopharma shares - Stock Titan
GLAZER CAPITAL, LLC Acquires Significant Stake in Day One Biopha - GuruFocus
Biggest stock movers Friday: MRVL, GAP, DAWN, GPRO, and more - MSN
SunOpta Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SunOpta Inc.STKL - Business Wire
Servier (DAWN) plans tender offer under March 6, 2026 merger agreement - Stock Titan
Aug Breakouts: Will Day One Biopharmaceuticals Inc stock go up in YEAR2026 Intraday Action & High Conviction Buy Zone Alerts - baoquankhu1.vn
Day One Biopharmaceuticals stock hits 52-week high at $21.44 By Investing.com - Investing.com Australia
Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 1-Year HighShould You Buy? - MarketBeat
Day One Biopharmaceuticals stock hits 52-week high at $21.44 - Investing.com
Glazer Capital (NASDAQ: DAWN) reports 5.6M-share, 5.44% stake - Stock Titan
Take Profit: Is Day One Biopharmaceuticals Inc a strong growth stockStock Surge & AI Driven Stock Reports - baoquankhu1.vn
Day One Biopharmaceuticals reiterates $225M–$250M OJEMDA revenue target as pipeline expands with Emi-Le integration - MSN
Day One Biopharmaceuticals Inc Stock (DAWN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):